Great report on infant formula (60 pages apparently) by Citi, a few weeks in and their 'view' is already looking very, very out of touch with reality.
And Goldman Sachs, "we believe this could impact 1HFY17E revenues for both A2M & BAL. We believe earnings risks for FY17E are skewed more to the downside..."
That 'belief' is looking a little unbelievable and plain wrong ATM...
- Forums
- ASX - By Stock
- BAL
- A2M AGM
A2M AGM, page-36
-
-
- There are more pages in this discussion • 175 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)